Rational application of the first ‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis

ConclusionsThe findings support the rationale for using pembrolizumab alone in the first ‐line treatment of PD‐L1 ≥ 50% advanced NSCLC due to the similar OS and lower grade ≥ 3 TRAEs. However, the combination of ICIs and chemotherapy is strongly recommended in patients with PD‐L1 ≤ 49% for significant survival benefit.

Source: Cancer Medicine - July 10, 2019 Category: Cancer & Oncology Authors: Rui Cao, Jie ‐Tao Ma, Shu‐Ling Zhang, Li Sun, Yang Liu, Xiang‐Yan Zhang, Wei Jing, Le‐Tian Huang, Cheng‐Bo Han Tags: ORIGINAL RESEARCH Source Type: research